Neoadjuvant Chemotherapy in Breast Cancer
Primary Purpose
Decision Support Systems, Clinical
Status
Recruiting
Phase
Not Applicable
Locations
Russian Federation
Study Type
Interventional
Intervention
Neoadjuvant Chemotherapy by CDSS (MedicBK)
General practice
Sponsored by

About this trial
This is an interventional treatment trial for Decision Support Systems, Clinical
Eligibility Criteria
Inclusion Criteria:
- Histologically confirmed infiltrating breast cancer
- Stage II or stage III disease. Nodal status must be examined by ultrasound, fine needle aspiration, sentinel node biopsy, or FDG-PET scan.
- Age ≥18
- Eastern Cooperative Oncology Group performance status ≤1
- Adequate bone marrow function (ANC >1.5 x 109/l, platelets >100 x 109/l)
- Adequate hepatic function (ALAT, ASAT and bilirubin <2.5 times upper limit of normal)
- Adequate renal function (creatinine clearance >50 ml/min)
- LVEF ≥50% measured by echocardiography or MUGA
- Absence of any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
- Absence of any medical condition that would place the patient at unusual risk.
- Signed written informed consent
Exclusion Criteria:
- previous radiation therapy or chemotherapy
- other malignancy except carcinoma in situ, unless the other malignancy was treated ≥5 years ago with curative intent without the use of chemotherapy or radiation therapy.
- current pregnancy or breastfeeding. Women of childbearing potential must use adequate contraceptive protection
- evidence of distant metastases. Evaluation of the presence of distant metastases may include chest X-ray, liver ultrasound, isotope bone-scan, CT-scan of chest and abdomen and/or FDG-PET scan, according to local procedures.
- evidence of bilateral infiltrating breast cancer. Evaluation of the presence of bilateral infiltrating breast cancer may include mammography, breast ultrasound and/or MRI breast.
- concurrent anti-cancer treatment or another investigational drug.
Sites / Locations
- Evgeny PokushalovRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Neoadjuvant Chemotherapy by CDSS
Neoadjuvant Chemotherapy in General practice
Arm Description
Outcomes
Primary Outcome Measures
Number of patients with pathological complete response
To compare the efficacy of Neoadjuvant Chemotherapy in general practice and by CDSS
Secondary Outcome Measures
Number of patients with grade >2 adverse events as a measure of safety and tolerability
to describe the safety of the various regimens toxicity is compared between the two arms
identify prognostic and predictive for pathological complete response
To identify prognostic and predictive for pathological complete response after neoadjuvant treatment
Full Information
NCT ID
NCT04802941
First Posted
March 12, 2021
Last Updated
March 16, 2021
Sponsor
Center of Personalized Medicine, Pirogova
Collaborators
Center for New Medical Technologies, Novosibirsk, Russia, I.M. Sechenov First Moscow State Medical University, Novosibirsk Oncology Center
1. Study Identification
Unique Protocol Identification Number
NCT04802941
Brief Title
Neoadjuvant Chemotherapy in Breast Cancer
Official Title
Optimizing Neoadjuvant Systemic Treatment for Breast Cancer by Clinical Decision Support System
Study Type
Interventional
2. Study Status
Record Verification Date
March 2021
Overall Recruitment Status
Recruiting
Study Start Date
March 12, 2021 (Actual)
Primary Completion Date
March 30, 2024 (Anticipated)
Study Completion Date
March 30, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Center of Personalized Medicine, Pirogova
Collaborators
Center for New Medical Technologies, Novosibirsk, Russia, I.M. Sechenov First Moscow State Medical University, Novosibirsk Oncology Center
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study compares two approaches of upfront chemotherapy in breast cancer.
Detailed Description
A Decision Support System (DSS) is an information system that supports business, medical, educational or organisational decision-making activities. DSSs fuse human knowledge and technology to support and improve decision-making.
The area of precision oncology that supports the treatment of breast cancer has not only seen an increase in the availability of different treatment choices but also genomic tools to support the decision-making process. CDSSs have been available for use in clinical oncology practice for over a decade. However, there has been some criticism around the utility of CDSS in personalised medicine decision-making of breast cancer, with these systems often viewed as aids better suited to support the 'average' patient's requirements rather than personalised treatment for the individual patient.
The purpose of the current study is to evaluate an innovative CDSS (MedicBK) platform based on the comparison of multiple treatments simultaneously in making care decisions taking into account the individual characteristics of patients, i.e., based on personalized evidence-based medicine.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Decision Support Systems, Clinical
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
1200 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Neoadjuvant Chemotherapy by CDSS
Arm Type
Experimental
Arm Title
Neoadjuvant Chemotherapy in General practice
Arm Type
Active Comparator
Intervention Type
Device
Intervention Name(s)
Neoadjuvant Chemotherapy by CDSS (MedicBK)
Intervention Description
CDSS (MedicBK) captures the patient-specific data required to determine appropriate care decisions from the EMR and then presents relevant data alongside treatment suggestions to clinicians. MedicBK uses algorithms for presenting treatment suggestions framed by guideline-based therapy and personalized personalized evidence-based therapy. MedicBK consists of three main blocks: database, network meta-analysis, and heterogeneity of treatment effects assessment.
Intervention Type
Drug
Intervention Name(s)
General practice
Intervention Description
General practice
Primary Outcome Measure Information:
Title
Number of patients with pathological complete response
Description
To compare the efficacy of Neoadjuvant Chemotherapy in general practice and by CDSS
Time Frame
at week 30
Secondary Outcome Measure Information:
Title
Number of patients with grade >2 adverse events as a measure of safety and tolerability
Description
to describe the safety of the various regimens toxicity is compared between the two arms
Time Frame
up to week 35
Title
identify prognostic and predictive for pathological complete response
Description
To identify prognostic and predictive for pathological complete response after neoadjuvant treatment
Time Frame
within one year after end of treatment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Histologically confirmed infiltrating breast cancer
Stage II or stage III disease. Nodal status must be examined by ultrasound, fine needle aspiration, sentinel node biopsy, or FDG-PET scan.
Age ≥18
Eastern Cooperative Oncology Group performance status ≤1
Adequate bone marrow function (ANC >1.5 x 109/l, platelets >100 x 109/l)
Adequate hepatic function (ALAT, ASAT and bilirubin <2.5 times upper limit of normal)
Adequate renal function (creatinine clearance >50 ml/min)
LVEF ≥50% measured by echocardiography or MUGA
Absence of any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
Absence of any medical condition that would place the patient at unusual risk.
Signed written informed consent
Exclusion Criteria:
previous radiation therapy or chemotherapy
other malignancy except carcinoma in situ, unless the other malignancy was treated ≥5 years ago with curative intent without the use of chemotherapy or radiation therapy.
current pregnancy or breastfeeding. Women of childbearing potential must use adequate contraceptive protection
evidence of distant metastases. Evaluation of the presence of distant metastases may include chest X-ray, liver ultrasound, isotope bone-scan, CT-scan of chest and abdomen and/or FDG-PET scan, according to local procedures.
evidence of bilateral infiltrating breast cancer. Evaluation of the presence of bilateral infiltrating breast cancer may include mammography, breast ultrasound and/or MRI breast.
concurrent anti-cancer treatment or another investigational drug.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Evgeny Pokushalov, Prof. MD PhD
Phone
89139254858
Email
e.pokushalov@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Irina Ostanina, MD
Phone
+79039031563
Facility Information:
Facility Name
Evgeny Pokushalov
City
Novosibirsk
ZIP/Postal Code
630090
Country
Russian Federation
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Evgeny Pokushalov, Prof. MD PhD
Phone
89139254858
Email
e.pokushalov@gmail.com
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Neoadjuvant Chemotherapy in Breast Cancer
We'll reach out to this number within 24 hrs